Marco Rovaris

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2246496/publications.pdf

Version: 2024-02-01

272	14,756	13865 67	24982 109
papers	citations	h-index	g-index

277	277	277	9729
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effects of home-based virtual reality telerehabilitation system in people with multiple sclerosis: A randomized controlled trial. Journal of Telemedicine and Telecare, 2024, 30, 344-355.	2.7	16
2	Effects of voice rehabilitation in people with MS: A double-blinded long-term randomized controlled trial. Multiple Sclerosis Journal, 2022, 28, 1081-1090.	3.0	3
3	Prevalence and patterns of subclinical motor and cognitive impairments in non-disabled individuals with early multiple sclerosis: A multicenter cross-sectional study. Annals of Physical and Rehabilitation Medicine, 2022, 65, 101491.	2.3	11
4	Physical activity in non-disabled people with early multiple sclerosis: A multicenter cross-sectional study. Multiple Sclerosis and Related Disorders, 2022, 64, 103941.	2.0	5
5	Social Cognition Training for Enhancing Affective and Cognitive Theory of Mind in Schizophrenia: A Systematic Review and a Meta-Analysis. Journal of Psychology: Interdisciplinary and Applied, 2021, 155, 26-58.	1.6	24
6	Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. Multiple Sclerosis Journal, 2021, 27, 430-438.	3.0	19
7	Neuroplasticity and Motor Rehabilitation in Multiple Sclerosis: A Systematic Review on MRI Markers of Functional and Structural Changes. Frontiers in Neuroscience, 2021, 15, 707675.	2.8	5
8	Walking With Horizontal Head Turns Is Impaired in Persons With Early-Stage Multiple Sclerosis Showing Normal Locomotion. Frontiers in Neurology, 2021, 12, 821640.	2.4	5
9	Integrated telerehabilitation approach in multiple sclerosis: A systematic review and meta-analysis. Journal of Telemedicine and Telecare, 2020, 26, 385-399.	2.7	58
10	Italian consensus on treatment of spasticity in multiple sclerosis. European Journal of Neurology, 2020, 27, 445-453.	3.3	20
11	Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 914-920.	1.9	5
12	Improved Gait of Persons With Multiple Sclerosis After Rehabilitation: Effects on Lower Limb Muscle Synergies, Push-Off, and Toe-Clearance. Frontiers in Neurology, 2020, 11, 668.	2.4	9
13	Mindfulness-Based Interventions for the Improvement of Well-Being in People With Multiple Sclerosis: A Systematic Review and Meta-Analysis. Psychosomatic Medicine, 2020, 82, 600-613.	2.0	14
14	The IN-DEEP project â€œINtegrating and Deriving Evidence, Experiences, Preferencesâ€• a web information model on magnetic resonance imaging for people with multiple sclerosis. Journal of Neurology, 2020, 267, 2421-2431.	3.6	1
15	Assessing balance in non-disabled subjects with multiple sclerosis: Validation of the Fullerton Advanced Balance Scale. Multiple Sclerosis and Related Disorders, 2020, 42, 102085.	2.0	6
16	Impaired heart rate recovery after sub-maximal physical exercise in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 40, 101960.	2.0	5
17	Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. Journal of Neurology, 2019, 266, 3098-3107.	3.6	1
18	Acute Fingolimod Effects on Baroreflex and Cardiovascular Autonomic Control in Multiple Sclerosis. Journal of Central Nervous System Disease, 2019, 11, 117957351984994.	1.9	5

#	Article	IF	Citations
19	A Deficit of CEACAM-1â€“Expressing T Lymphocytes Supports Inflammation in Primary Progressive Multiple Sclerosis. Journal of Immunology, 2019, 203, 76-83.	0.8	9
20	Predictors of hospital-based multidisciplinary rehabilitation effects in persons with multiple sclerosis: a large-scale, single-centre study. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731984367.	1.0	4
21	The Effects of Transcutaneous Spinal Direct Current Stimulation on Neuropathic Pain in Multiple Sclerosis: Clinical and Neurophysiological Assessment. Frontiers in Human Neuroscience, 2019, 13, 31.	2.0	24
22	Effect of arm cycling and task-oriented exercises on fatigue and upper limb performance in multiple sclerosis: a randomized crossover study. International Journal of Rehabilitation Research, 2019, 42, 300-308.	1.3	7
23	A simple and universal enzyme-free approach for the detection of multiple microRNAs using a single nanostructured enhancer of surface plasmon resonance imaging. Analytical and Bioanalytical Chemistry, 2019, 411, 1873-1885.	3.7	36
24	The Italian multiple sclerosis register. Neurological Sciences, 2019, 40, 155-165.	1.9	59
25	Longitudinal associations between mindfulness and well-being in people with multiple sclerosis. International Journal of Clinical and Health Psychology, 2019, 19, 22-30.	5.1	47
26	Online meditation training for people with multiple sclerosis: A randomized controlled trial. Multiple Sclerosis Journal, 2019, 25, 610-617.	3.0	55
27	Effects of motor rehabilitation on mobility and brain plasticity in multiple sclerosis: a structural and functional MRI study. Journal of Neurology, 2018, 265, 1393-1401.	3.6	54
28	HLA alleles modulate EBV viral load in multiple sclerosis. Journal of Translational Medicine, 2018, 16, 80.	4.4	44
29	Prediction of Falls in Subjects Suffering From Parkinson Disease, Multiple Sclerosis, and Stroke. Archives of Physical Medicine and Rehabilitation, 2018, 99, 641-651.	0.9	51
30	Intensive Multimodal Training to Improve Gait Resistance, Mobility, Balance and Cognitive Function in Persons With Multiple Sclerosis: A Pilot Randomized Controlled Trial. Frontiers in Neurology, 2018, 9, 800.	2.4	37
31	Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study. Journal of Neurology, 2018, 265, 1850-1859.	3.6	33
32	Cardiac autonomic function during postural changes and exercise in people with multiple sclerosis: A cross-sectional study. Multiple Sclerosis and Related Disorders, 2018, 24, 85-90.	2.0	7
33	Response to Letter â€œPrediction of Falls in Subjects Suffering From Parkinson Disease, Multiple Sclerosis, and Stroke: Methodologic Issuesâ€• Archives of Physical Medicine and Rehabilitation, 2018, 99, 1688-1689.	0.9	1
34	Monosodium Urate Crystals Activate the Inflammasome in Primary Progressive Multiple Sclerosis. Frontiers in Immunology, 2018, 9, 983.	4.8	29
35	White Matter Tract Injury is Associated with Deep Gray Matter Iron Deposition in Multiple Sclerosis. Journal of Neuroimaging, 2017, 27, 107-113.	2.0	25
36	Indoleamine-2,3-dioxygenase(IDO)2 polymorphisms are not associated with multiple sclerosis in Italians. Journal of the Neurological Sciences, 2017, 377, 31-34.	0.6	8

#	Article	IF	Citations
37	Long-term disability progression in primary progressive multiple sclerosis: a 15-year study. Brain, 2017, 140, 2814-2819.	7.6	51
38	The still under-investigated role of cognitive deficits in PML diagnosis. Multiple Sclerosis and Demyelinating Disorders, 2017, 2, .	1.1	4
39	Multidisciplinary Rehabilitation is Efficacious and Induces Neural Plasticity in Multiple Sclerosis even when Complicated by Progressive Multifocal Leukoencephalopathy. Frontiers in Neurology, 2017, 8, 491.	2.4	4
40	Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study). PLoS ONE, 2017, 12, e0180651.	2.5	24
41	Are Modular Activations Altered in Lower Limb Muscles of Persons with Multiple Sclerosis during Walking? Evidence from Muscle Synergies and Biomechanical Analysis. Frontiers in Human Neuroscience, 2016, 10, 620.	2.0	42
42	Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 944-951.	1.9	88
43	B Lymphocytes in Multiple Sclerosis: Bregs and BTLA/CD272 Expressing-CD19+ Lymphocytes Modulate Disease Severity. Scientific Reports, 2016, 6, 29699.	3.3	34
44	Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. The Cochrane Library, 2016, 2016, CD009333.	2.8	46
45	6-Month Effects of Fingolimod on Indexes of Cardiovascular Autonomic Control in Multiple Sclerosis. Journal of the American College of Cardiology, 2016, 68, 2027-2029.	2.8	6
46	A semi-automated measuring system of brain diffusion and perfusion magnetic resonance imaging abnormalities in patients with multiple sclerosis based on the integration of coregistration and tissue segmentation procedures. BMC Medical Imaging, 2016, 16, 4.	2.7	4
47	Response to letter regarding article â€˜Fingolimod effects on left ventricular function in multiple sclerosisâ€™. Multiple Sclerosis Journal, 2016, 22, 708-709.	3.0	0
48	A telemedicine meditation intervention for people with multiple sclerosis and their caregivers: study protocol for a randomized controlled trial. Trials, 2016, 17, 4.	1.6	22
49	Diagnostic tools for assessment of urinary dysfunction in MS patients without urinary disturbances. Neurological Sciences, 2016, 37, 437-442.	1.9	7
50	Fingolimod effects on left ventricular function in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 201-211.	3.0	23
51	Modular organization of lower limbs in persons with multiple sclerosis and healthy persons during walking. Gait and Posture, 2015, 42, S14-S15.	1.4	1
52	MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression. Journal of Translational Medicine, 2015, 13, 148.	4.4	45
53	Corticospinal tract integrity is related to primary motor cortex thinning in relapsingâ€“remitting multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1771-1780.	3.0	34
54	Comparative efficacy of interferon Î² versus glatiramer acetate for relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1016-1020.	1.9	13

#	Article	IF	Citations
55	Grey matter damage in progressive multiple sclerosis versus amyotrophic lateral sclerosis: a voxel-based morphometry MRI study. Neurological Sciences, 2015, 36, 371-377.	1.9	13
56	Indoleamine 2,3 Dioxygenase (IDO) Expression and Activity in Relapsing- Remitting Multiple Sclerosis. PLoS ONE, 2015, 10, e0130715.	2.5	69
57	A role for the TIMâ€3/GALâ€9/BAT3 pathway in determining the clinical phenotype of multiple sclerosis. FASEB Journal, 2014, 28, 5000-5009.	0.5	30
58	Determinants of Disability in Multiple Sclerosis: An Immunological and MRI Study. BioMed Research International, 2014, 2014, 1-8.	1.9	13
59	Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. Multiple Sclerosis Journal, 2014, 20, 72-80.	3.0	95
60	The Peripheral Network between Oxidative Stress and Inflammation in Multiple Sclerosis. European Journal of Inflammation, 2014, 12, 351-363.	0.5	5
61	Surface-based reconstruction and diffusion MRI in the assessment of gray and white matter damage in multiple sclerosis. , 2014, , .		0
62	Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: A longitudinal study. Multiple Sclerosis Journal, 2014, 20, 1900-1903.	3.0	52
63	Oxidative Stress Is Differentially Present in Multiple Sclerosis Courses, Early Evident, and Unrelated to Treatment. Journal of Immunology Research, 2014, 2014, 1-9.	2.2	48
64	Predictors of effectiveness of multidisciplinary rehabilitation treatment on motor dysfunction in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 862-870.	3.0	11
65	A role for regulatory B cells in preventing the progression of Multiple Sclerosis. Journal of Neuroimmunology, 2014, 275, 12-13.	2.3	0
66	Up-regulation of Nod Like Receptors-3 signaling in multiple sclerosis disease. Journal of Neuroimmunology, 2014, 275, 87.	2.3	0
67	Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. , 2014, , CD009333.		18
68	Drug therapy for multiple sclerosis. Cmaj, 2014, 186, 833-840.	2.0	17
69	Insights from magnetic resonance imaging. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 115-149.	1.8	19
70	Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. BMC Neurology, 2014, 14, 65.	1.8	47
71	Toll-like receptor 3 differently modulates inflammation in progressive or benign multiple sclerosis. Clinical Immunology, 2014, 150, 109-120.	3.2	16
72	A novel data mining system points out hidden relationships between immunological markers in multiple sclerosis. Immunity and Ageing, 2013, 10, 1.	4.2	26

#	Article	IF	Citations
73	Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. Journal of Neurology, 2013, 260, 2458-2471.	3.6	96
74	Mitoxantrone for multiple sclerosis. The Cochrane Library, 2013, , CD002127.	2.8	75
75	T helper-17 activation dominates the immunologic milieu of both amyotrophic lateral sclerosis and progressive multiple sclerosis. Clinical Immunology, 2013, 148, 79-88.	3.2	56
76	Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. Neurological Sciences, 2013, 34, 1633-1637.	1.9	20
77	Interferon Â for secondary progressive multiple sclerosis: a systematic review. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 420-426.	1.9	47
78	Adverse events after endovascular treatment of chronic cerebro-spinal venous insufficiency (CCSVI) in patients with multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 961-963.	3.0	17
79	TH17-Driven Inflammation is Present in All Clinical Forms of Multiple Sclerosis; Disease Quiescence is Associated with Gata3-Expressing Cells. European Journal of Inflammation, 2013, 11, 223-235.	0.5	7
80	MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nature Reviews Neurology, 2012, 8, 13-21.	10.1	67
81	Assessment of Disease Activity in Multiple Sclerosis Phenotypes with Combined Gadolinium- and Superparamagnetic Iron Oxideâ€“enhanced MR Imaging. Radiology, 2012, 264, 225-233.	7.3	75
82	Modulation of the central memory and Tr1-like regulatory T cells in multiple sclerosis patients responsive to interferon-beta therapy. Multiple Sclerosis Journal, 2012, 18, 788-798.	3.0	19
83	JC virus detection and JC virus-specific immunity in natalizumab-treated Multiple Sclerosis patients. Journal of Translational Medicine, 2012, 10, 248.	4.4	18
84	Interferon beta for secondary progressive multiple sclerosis. The Cochrane Library, 2012, 1, CD005181.	2.8	57
85	Signal-to-noise ratio of diffusion weighted magnetic resonance imaging: Estimation methods and in vivo application to spinal cord. Biomedical Signal Processing and Control, 2012, 7, 285-294.	5.7	10
86	Atlasâ€Based Versus Individualâ€Based Fiber Tracking of the Corpus Callosum in Patients with Multiple Sclerosis: Reliability and Clinical Correlations. Journal of Neuroimaging, 2012, 22, 355-364.	2.0	6
87	T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 72-77.	1.9	53
88	Opposite effects of interferon-beta on new B and T cell release from production sites in multiple sclerosis patients. Journal of Neuroimmunology, 2011, 240-241, 147-150.	2.3	14
89	Relationship between brain MRI lesion load and short-term disease evolution in non-disabling MS: a large-scale, multicentre study. Multiple Sclerosis Journal, 2011, 17, 319-326.	3.0	11
90	Intercenter differences in diffusion tensor MRI acquisition. Journal of Magnetic Resonance Imaging, 2010, 31, 1458-1468.	3.4	81

#	Article	IF	Citations
91	A diffusion tensor MRI study of cervical cord damage in benign and secondary progressive multiple sclerosis patients. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 26-30.	1.9	38
92	Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology, 2010, 74, 1868-1876.	1.1	284
93	MRI criteria for MS in patients with clinically isolated syndromes. Neurology, 2010, 74, 427-434.	1.1	231
94	DTI Parameter Optimisation for Acquisition at 1.5T: SNR Analysis and Clinical Application. Computational Intelligence and Neuroscience, 2010, 2010, 1-8.	1.7	25
95	Costimulatory Pathways in Multiple Sclerosis: Distinctive Expression of PD-1 and PD-L1 in Patients with Different Patterns of Disease. Journal of Immunology, 2009, 183, 4984-4993.	0.8	83
96	Atlas-based vs. individual-based deterministic tractography of corpus callosum in multiple sclerosis. , 2009, 2009, 2699-702.		1
97	Primary progressive multiple sclerosis diagnostic criteria: a reappraisal. Multiple Sclerosis Journal, 2009, 15, 1459-1465.	3.0	35
98	A reassessment of the plateauing relationship between T2 lesion load and disability in MS. Neurology, 2009, 73, 1538-1542.	1.1	34
99	Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study. Multiple Sclerosis Journal, 2009, 15, 36-41.	3.0	78
100	A Single, Early Magnetic Resonance Imaging Study in the Diagnosis of Multiple Sclerosis. Archives of Neurology, 2009, 66, 587-92.	4.5	114
101	In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 789-794.	3.0	22
102	Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?. Multiple Sclerosis Journal, 2009, 15, 465-471.	3.0	15
103	MRI features of benign multiple sclerosis. Neurology, 2009, 72, 1693-1701.	1.1	48
104	Corpus callosum damage and cognitive dysfunction in benign MS. Human Brain Mapping, 2009, 30, 2656-2666.	3.6	99
105	Diffusion Tensor MR Imaging. Neuroimaging Clinics of North America, 2009, 19, 37-43.	1.0	73
106	The definition of non-responder to multiple sclerosis treatment: neuroimaging markers. Neurological Sciences, 2008, 29, 222-224.	1.9	5
107	MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain. Journal of Neurology, 2008, 255, 1-10.	3.6	80
108	A 3-year diffusion tensor MRI study of grey matter damage progression during the earliest clinical stage of MS. Journal of Neurology, 2008, 255, 1209-1214.	3.6	36

#	Article	IF	Citations
109	Agreement between different input image types in brain atrophy measurement in multiple sclerosis using SIENAX and SIENA. Journal of Magnetic Resonance Imaging, 2008, 28, 559-565.	3.4	19
110	Predicting progression in primary progressive multiple sclerosis: A 10â€year multicenter study. Annals of Neurology, 2008, 63, 790-793.	5.3	101
111	Will Rogers phenomenon in multiple sclerosis. Annals of Neurology, 2008, 64, 428-433.	5.3	80
112	Morphology and evolution of cortical lesions in multiple sclerosis. A longitudinal MRI study. NeuroImage, 2008, 42, 1324-1328.	4.2	55
113	Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet, The, 2008, 371, 2085-2092.	13.7	265
114	Cognitive impairment and structural brain damage in benign multiple sclerosis. Neurology, 2008, 71, 1521-1526.	1.1	85
115	Absence of diffuse cervical cord tissue damage in early, non-disabling relapsing-remitting MS: a preliminary study. Multiple Sclerosis Journal, 2008, 14, 853-856.	3.0	13
116	Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 455-464.	3.0	58
117	A Magnetic Resonance Imaging Voxel-Based Morphometry Study of Regional Gray Matter Atrophy in Patients With Benign Multiple Sclerosis. Archives of Neurology, 2008, 65, 1223-30.	4.5	64
118	Impaired Short-term Motor Learning in Multiple Sclerosis: Evidence From Virtual Reality. Neurorehabilitation and Neural Repair, 2007, 21, 273-278.	2.9	54
119	Assessing "occult" cervical cord damage in patients with neuropsychiatric systemic lupus erythematosus using diffusion tensor MRI. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 893-895.	1.9	7
120	A composite score to predict short-term disease activity in patients with relapsing-remitting MS. Neurology, 2007, 69, 1230-1235.	1.1	33
121	Serial Whole-Brain N-Acetylaspartate Concentration in Healthy Young Adults. American Journal of Neuroradiology, 2007, 28, 1650-1651.	2.4	17
122	Determinants of Disability in Multiple Sclerosis at Various Disease Stages. Archives of Neurology, 2007, 64, 1163.	4.5	47
123	Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial. Multiple Sclerosis Journal, 2007, 13, 502-508.	3.0	53
124	Incorporating Domain Knowledge Into the Fuzzy Connectedness Framework: Application to Brain Lesion Volume Estimation in Multiple Sclerosis. IEEE Transactions on Medical Imaging, 2007, 26, 1670-1680.	8.9	20
125	Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsingâ€“remitting MS. Neurology, 2007, 68, 939-944.	1.1	45
126	Antonâ€™s Syndrome following Callosal Disconnection. Behavioural Neurology, 2007, 18, 183-186.	2.1	13

#	Article	IF	Citations
127	Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manuallyâ€edited SIENA and SIENAX. Journal of Magnetic Resonance Imaging, 2007, 26, 881-885.	3.4	45
128	Diffusion Tensor MRI in Multiple Sclerosis. Journal of Neuroimaging, 2007, 17, 27S-30S.	2.0	59
129	MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurology, The, 2007, 6, 677-686.	10.2	292
130	A brain magnetization transfer MRI study with a clinical follow up of about four years in patients with clinically isolated syndromes suggestive of multiple sclerosis. Journal of Neurology, 2007, 254, 78-83.	3.6	16
131	Normal-appearing white and grey matter damage in MS. Journal of Neurology, 2007, 254, 513-518.	3.6	73
132	Diffusion-Weighted Imaging. , 2007, , 65-74.		0
133	MRI markers of destructive pathology in multiple sclerosis-related cognitive dysfunction. Journal of the Neurological Sciences, 2006, 245, 111-116.	0.6	68
134	Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurology, The, 2006, 5, 343-354.	10.2	246
135	MRI and the diagnosis of multiple sclerosis: expanding the concept of â€œno better explanationâ€. Lancet Neurology, The, 2006, 5, 841-852.	10.2	217
136	Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain, 2006, 129, 2620-2627.	7.6	143
137	Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years. Brain, 2006, 129, 2628-2634.	7.6	122
138	Multimodal evoked potentials to assess the evolution of multiple sclerosis: a longitudinal study. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 1030-1035.	1.9	130
139	Influence of aging on brain gray and white matter changes assessed by conventional, MT, and DT MRI. Neurology, 2006, 66, 535-539.	1.1	109
140	Axonal Injury and Overall Tissue Loss Are Not Related in Primary Progressive Multiple Sclerosis. Archives of Neurology, 2005, 62, 898-902.	4.5	36
141	Diffusion-Tensor Magnetic Resonance Imaging Detects Normal-Appearing White Matter Damage Unrelated to Short-term Disease Activity in Patients at the Earliest Clinical Stage of Multiple Sclerosis. Archives of Neurology, 2005, 62, 803.	4.5	101
142	Immunological patterns identifying disease course and evolution in multiple sclerosis patients. Journal of Neuroimmunology, 2005, 165, 192-200.	2.3	38
143	Defining the response to multiple sclerosis treatment: the role of conventional magnetic resonance imaging. Neurological Sciences, 2005, 26, s204-s208.	1.9	10
144	Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution. Neurology, 2005, 65, 1626-1630.	1.1	48

#	Article	IF	Citations
145	Long-term clinical outcome of primary progressive MS: Predictive value of clinical and MRI data. Neurology, 2005, 65, 633-635.	1.1	59
146	Evidence for progressive gray matter loss in patients with relapsing-remitting MS. Neurology, 2005, 65, 1126-1128.	1.1	72
147	Quantification of cervical cord pathology in primary progressive MS using diffusion tensor MRI. Neurology, 2005, 64, 631-635.	1.1	99
148	Diffusion MRI in multiple sclerosis. Neurology, 2005, 65, 1526-1532.	1.1	252
149	Progressive Gray Matter Damage in Patients With Relapsing-Remitting Multiple Sclerosis. Archives of Neurology, 2005, 62, 578.	4.5	103
150	Movement preparation is affected by tissue damage in multiple sclerosis: Evidence from EEG event-related desynchronization. Clinical Neurophysiology, 2005, 116, 1515-1519.	1.5	22
151	Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI. NeuroImage, 2005, 24, 1139-1146.	4.2	106
152	Mean diffusivity and fractional anisotropy histogram analysis of the cervical cord in MS patients. NeuroImage, 2005, 26, 822-828.	4.2	123
153	Glatiramer acetate in multiple sclerosis. Expert Review of Neurotherapeutics, 2005, 5, 451-458.	2.8	5
154	Can glatiramer acetate reduce brain atrophy development in multiple sclerosis?. Journal of the Neurological Sciences, 2005, 233, 139-143.	0.6	7
155	â€œImportance samplingâ€• A strategy to overcome the clinical/MRI paradox in MS?. Journal of the Neurological Sciences, 2005, 237, 1-3.	0.6	6
156	Mitoxantrone for multiple sclerosis. , 2005, , CD002127.		29
157	White Matter Pathology in Systemic Immune-Mediated Diseases. , 2005, , 343-352.		0
158	Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype. American Journal of Neuroradiology, 2005, 26, 341-6.	2.4	113
159	Diffusion imaging in demyelination and inflammation. , 2004, , 444-459.		0
160	Imaging primary progressive multiple sclerosis: the contribution of structural, metabolic, and functional MRI techniques. Multiple Sclerosis Journal, 2004, 10, S36-S45.	3.0	33
161	The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials. Multiple Sclerosis Journal, 2004, 10, 341-347.	3.0	20
162	An MT MRI study of the cervical cord in clinically isolated syndromes suggestive of MS. Neurology, 2004, 63, 584-585.	1.1	42

#	Article	IF	Citations
163	Diffusion tensor MRI of the cervical cord in a patient with syringomyelia and multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1647-1647.	1.9	14
164	Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology, 2004, 62, 1432-1434.	1.1	113
165	Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2004, 364, 1489-1496.	13.7	246
166	A new method for analyzing histograms of brain magnetization transfer ratios: comparison with existing techniques. American Journal of Neuroradiology, 2004, 25, 1234-41.	2.4	10
167	Occult tissue damage in patients with primary progressive multiple sclerosis is independent of T2-visible lesions. Journal of Neurology, 2003, 250, 456-460.	3.6	56
168	Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon Î²1a. Annals of Neurology, 2003, 53, 718-724.	5.3	120
169	A diffusion tensor MRI study of basal ganglia from patients with ADEM. Journal of the Neurological Sciences, 2003, 206, 27-30.	0.6	20
170	Whole-brain atrophy in multiple sclerosis measured by two segmentation processes from various MRI sequences. Journal of the Neurological Sciences, 2003, 216, 169-177.	0.6	47
171	Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. Multiple Sclerosis Journal, 2003, 9, 349-355.	3.0	72
172	Somatosensory evoked potentials and sensory involvement in multiple sclerosis: comparison with clinical findings and quantitative sensory tests. Multiple Sclerosis Journal, 2003, 9, 275-279.	3.0	33
173	Interventions for the Prevention of Brain Atrophy in Multiple Sclerosis. CNS Drugs, 2003, 17, 563-575.	5.9	14
174	beta endorphin concentrations in PBMC of patients with different clinical phenotypes of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 495-497.	1.9	14
175	The effect of interferon Î²-1b on quantities derived from MT MRI in secondary progressive MS. Neurology, 2003, 60, 853-860.	1.1	84
176	Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study. Brain, 2003, 126, 2323-2332.	7.6	122
177	Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain, 2003, 126, 433-437.	7.6	324
178	Age-related Changes in Conventional, Magnetization Transfer, and Diffusion-Tensor MR Imaging Findings: Study with Whole-Brain Tissue Histogram Analysis1ÂÂ. Radiology, 2003, 227, 731-738.	7.3	134
179	Magnetic resonance-based techniques for the study and management of multiple sclerosis. British Medical Bulletin, 2003, 65, 133-144.	6.9	12
180	Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis. American Journal of Neuroradiology, 2003, 24, 75-81.	2.4	24

#	Article	IF	Citations
181	Two-year follow-up study of primary and transitional progressive multiple sclerosis. Multiple Sclerosis Journal, 2002, 8, 108-114.	3.0	43
182	Glatiramer acetate reduces the proportion of new MS lesions evolving into â€œblack holesâ€• Neurology, 2002, 58, 1440-1442.	1.1	136
183	Assessment of Normal-Appearing White and Gray Matter in Patients With Primary Progressive Multiple Sclerosis. Archives of Neurology, 2002, 59, 1406-12.	4.5	180
184	Contribution of cervical cord MRI and brain magnetization transfer imaging to the assessment of individual patients with multiple sclerosis: a preliminary study. Multiple Sclerosis Journal, 2002, 8, 52-58.	3.0	15
185	Frequency and patterns of subclinical cognitive impairment in patients with ANCA-associated small vessel vasculitides. Journal of the Neurological Sciences, 2002, 195, 161-166.	0.6	35
186	Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses. Neurology, 2002, 59, 1429-1432.	1.1	26
187	Cognitive dysfunction in patients with mildly disabling relapsingâ€“remitting multiple sclerosis: an exploratory study with diffusion tensor MR imaging. Journal of the Neurological Sciences, 2002, 195, 103-109.	0.6	208
188	Clinical trials and clinical practice in multiple sclerosis: Conventional and emerging magnetic resonance imaging technologies. Current Neurology and Neuroscience Reports, 2002, 2, 267-276.	4.2	6
189	Magnetic Resonance Imaging of Multiple Sclerosis. Journal of Neuroimaging, 2002, 12, 289-301.	2.0	26
190	MR-based technology for in vivo detection, characterization, and quantification of pathology of relapsing-remitting multiple sclerosis. Journal of Rehabilitation Research and Development, 2002, 39, 243-59.	1.6	4
191	Sample size estimations for MRI-monitored trials of MS comparing new vs standard treatments. Neurology, 2001, 57, 1883-1885.	1.1	15
192	An MR study of tissue damage in the cervical cord of patients with migraine. Journal of the Neurological Sciences, 2001, 183, 43-46.	0.6	34
193	The role of non-conventional MR techniques to study multiple sclerosis patients. Journal of the Neurological Sciences, 2001, 186, S3-S9.	0.6	15
194	Magnetization transfer and diffusion tensor MR imaging of the optic radiations and calcarine cortex from patients with Leber's hereditary optic neuropathy. Journal of the Neurological Sciences, 2001, 188, 33-36.	0.6	8
195	Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet, The, 2001, 357, 1576-1582.	13.7	1,025
196	Short-term brain volume change in relapsing-remitting multiple sclerosis: Effect of glatiramer acetate and implications. Brain, 2001, 124, 1803-1812.	7.6	143
197	Correlations Between Clinical Findings and Magnetization Transfer Imaging Metrics of Tissue Damage in Individuals With Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy. Stroke, 2001, 32, 643-648.	2.0	56
198	Neuroimaging techniques in the diagnostic work-up of patients with the antiphospholipid syndrome. Current Rheumatology Reports, 2001, 3, 301-306.	4.7	4

#	Article	IF	Citations
199	Differential diagnosis of posterior fossa multiple sclerosis lesions - neuroradiological aspects. Neurological Sciences, 2001, 22, S79-S83.	1.9	20
200	Clinical and MRI assessment of brain damage in MS. Neurological Sciences, 2001, 22, S123-S127.	1.9	12
201	Effects of seasons on magnetic resonance imagingâ€“measured disease activity in patients with multiple sclerosis. Annals of Neurology, 2001, 49, 415-416.	5.3	32
202	Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 494-499.	1.9	54
203	In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis. Brain, 2001, 124, 2540-2549.	7.6	163
204	Delivery to the Central Nervous System of a Nonreplicative Herpes Simplex Type 1 Vector Engineered with the Interleukin 4 Gene Protects Rhesus Monkeys from Hyperacute Autoimmune Encephalomyelitis. Human Gene Therapy, 2001, 12, 905-920.	2.7	57
205	Magnetic resonance imaging, magnetisation transfer imaging, and diffusion weighted imaging correlates of optic nerve, brain, and cervical cord damage in Leber's hereditary optic neuropathy. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 444-449.	1.9	68
206	Glatiramer acetate reduces the proportion of new MS lesions evolving into â€œblack holesâ€• Neurology, 2001, 57, 731-733.	1.1	274
207	Intra-observer, inter-observer and inter-scanner variations in brain MRI volume measurements in multiple sclerosis. Multiple Sclerosis Journal, 2001, 7, 27-31.	3.0	2
208	Modelling new enhancing MRI lesion counts in multiple sclerosis. Multiple Sclerosis Journal, 2001, 7, 298-304.	3.0	6
209	Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology, 2000, 55, 1714-1718.	1.1	124
210	The value of new magnetic resonance techniques in multiple sclerosis. Current Opinion in Neurology, 2000, 13, 249-254.	3.6	23
211	A comparison of the sensitivity of MRI after double- and triple-dose Gd-DTPA for detecting enhancing lesions in multiple sclerosisâ˜†. Magnetic Resonance Imaging, 2000, 18, 761-763.	1.8	21
212	Detection of multiple sclerosis lesions using EPI-FLAIR images. Magnetic Resonance Imaging, 2000, 18, 907-910.	1.8	6
213	The contribution of fast-FLAIR MRI for lesion detection in the brain of patients with systemic autoimmune diseases. Journal of Neurology, 2000, 247, 29-33.	3.6	24
214	Sensitivity and reproducibility of volume change measurements of different brain portions on magnetic resonance imaging in patients with multiple sclerosis. Journal of Neurology, 2000, 247, 960-965.	3.6	51
215	MRI and motor evoked potential findings in nondisabled multiple sclerosis patients with and without symptoms of fatique. Journal of Neurology, 2000, 247, 506-509.	3.6	122
216	One year follow up study of primary and transitional progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 68, 713-718.	1.9	106

#	Article	IF	Citations
217	Relative contributions of brain and cervical cord pathology to multiple sclerosis disability: a study with magnetisation transfer ratio histogram analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 69, 723-727.	1.9	78
218	Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 68, 157-161.	1.9	171
219	Magnetization transfer imaging to monitor the evolution of MS. Neurology, 2000, 55, 940-946.	1.1	145
220	Electroencephalographic coherence analysis in multiple sclerosis: correlation with clinical, neuropsychological, and MRI findings. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 69, 192-198.	1.9	101
221	Brain involvement in systemic immune mediated diseases: magnetic resonance and magnetisation transfer imaging study. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 68, 170-177.	1.9	107
222	The effect of cladribine on T1 â€˜black holeâ€™ changes in progressive MS. Journal of the Neurological Sciences, 2000, 176, 42-44.	0.6	64
223	Cervical cord magnetic resonance imaging findings in systemic immune-mediated diseases. Journal of the Neurological Sciences, 2000, 176, 128-130.	0.6	25
224	The role of magnetic resonance in the assessment of multiple sclerosis. Journal of the Neurological Sciences, 2000, 172, S3-S12.	0.6	8
225	Assessment of the damage of the cerebral hemispheres in MS using neuroimaging techniques. Journal of the Neurological Sciences, 2000, 172, S63-S66.	0.6	21
226	Interferon beta treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 67, 386-389.	1.9	22
227	Reproducibility of Brain MRI Lesion Volume Measurements in Multiple Sclerosis Using a Local Thresholding Technique: Effects of Formal Operator Training. European Neurology, 1999, 41, 226-230.	1.4	12
228	Correlation between MRI and Short-Term Clinical Activity in Multiple Sclerosis: Comparison between Standard- and Triple-Dose Gd-Enhanced MRI. European Neurology, 1999, 41, 123-127.	1.4	14
229	A longitudinal study comparing the sensitivity of CSE and RARE sequences in detecting new multiple sclerosis lesions. Magnetic Resonance Imaging, 1999, 17, 457-458.	1.8	4
230	Correlation between enhancing lesion number and volume on standard and triple dose gadolinium-enhanced brain MRI scans from patients with multiple sclerosis. Magnetic Resonance Imaging, 1999, 17, 985-988.	1.8	8
231	Lesion load quantification on fast-FLAIR, rapid acquisition relaxation-enhanced, and gradient spin echo brain MRI scans from multiple sclerosis patients. Magnetic Resonance Imaging, 1999, 17, 1105-1110.	1.8	16
232	Method for intracellular magnetic labeling of human mononuclear cells using approved iron contrast agents. Magnetic Resonance Imaging, 1999, 17, 1521-1523.	1.8	69
233	Neuroimaging in amyotrophic lateral sclerosis. European Journal of Neurology, 1999, 6, 629-637.	3.3	48
234	A comparison of the sensitivity of monthly unenhanced and enhanced MRI techniques in detecting new multiple sclerosis lesions. Journal of Neurology, 1999, 246, 97-106.	3.6	9

#	Article	IF	Citations
235	Fatigue and magnetic resonance imaging activity in multiple sclerosis. Journal of Neurology, 1999, 246, 454-458.	3.6	104
236	Multiple sclerosis: interobserver agreement in reporting active lesions on serial brain MRI using conventional spin echo, fast spin echo, fast fluid-attenuated inversion recovery and post-contrast T1-weighted images. Journal of Neurology, 1999, 246, 920-925.	3.6	12
237	Short-term evolution of new multiple sclerosis lesions enhancing on standard and triple dose gadolinium-enhanced brain MRI scans. Journal of the Neurological Sciences, 1999, 164, 148-152.	0.6	16
238	Brain MRI correlates of magnetization transfer imaging metrics in patients with multiple sclerosis. Journal of the Neurological Sciences, 1999, 166, 58-63.	0.6	28
239	Quantitative brain volumetric analysis from patients with multiple sclerosis: a follow-up study. Journal of the Neurological Sciences, 1999, 171, 8-10.	0.6	21
240	Cumulative effect of a weekly low dose of interferon beta 1a on standard and triple dose contrast-enhanced MRI from multiple sclerosis patients. Journal of the Neurological Sciences, 1999, 171, 130-134.	0.6	15
241	A multiparametric MRI study of frontal lobe dementia in multiple sclerosis. Journal of the Neurological Sciences, 1999, 171, 135-144.	0.6	48
242	Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis. Current Opinion in Neurology, 1999, 12, 337-344.	3.6	80
243	The effect of repositioning on brain MRI lesion load assessment in multiple sclerosis: reliability of subjective quality criteria. Journal of Neurology, 1998, 245, 273-275.	3.6	16
244	How does brain MRI lesion volume change on serial scans in patients with multiple sclerosis?. Magnetic Resonance Imaging, 1998, 16, 1181-1183.	1.8	3
245	Brain MRI lesion volume measurement reproducibility is not dependent on the disease burden in patients with multiple sclerosis. Magnetic Resonance Imaging, 1998, 16, 1185-1189.	1.8	3
246	EEG correlates of cognitive impairment in MS. Italian Journal of Neurological Sciences, 1998, 19, S413-S417.	0.1	4
247	A longitudinal brain MRI study comparing the sensitivities of the conventional and a newer approach for detecting active lesions in multiple sclerosis. Journal of the Neurological Sciences, 1998, 159, 94-101.	0.6	11
248	Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. Neurology, 1998, 50, 1601-1608.	1.1	253
249	Magnetization transfer ratios in multiple sclerosis lesions enhancing after different doses of gadolinium. Neurology, 1998, 50, 1289-1293.	1.1	81
250	Detecting New Lesion Formation in Multiple Sclerosis: The Relative Contributions of Monthly Dual-Echo and T₁-Weighted Scans after Triple-Dose Gadolinium. European Neurology, 1998, 40, 146-150.	1.4	4
251	A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. Brain, 1998, 121, 2011-2020.	7.6	123
252	A Preliminary Study Comparing the Sensitivity of Serial Monthly Enhanced MRI After Standard and Triple Dose Gadoliniumâ€DTPA for Monitoring Disease Activity in Primary Progressive Multiple Sclerosis. Journal of Neuroimaging, 1998, 8, 88-93.	2.0	14

#	Article	IF	Citations
253	A Comparison Between the Sensitivities of 3â€mm and 5â€mm Thick Serial Brain MRI for Detecting Lesion Volume Changes in Patients with Multiple Sclerosis. Journal of Neuroimaging, 1998, 8, 144-147.	2.0	9
254	MRI evolution of new MS lesions enhancing after different doses of gadolinium. Acta Neurologica Scandinavica, 1998, 98, 90-93.	2.1	15
255	Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis. Neurology, 1997, 49, 1682-1688.	1.1	103
256	The influence of slice orientation on brain MRI lesion load measurement in multiple sclerosis. Multiple Sclerosis Journal, 1997, 3, 382-384.	3.0	1
257	A Longitudinal Magnetic Resonance Imaging Study of the Cervical Cord in Multiple Sclerosis. Journal of Neuroimaging, 1997, 7, 78-80.	2.0	37
258	Sensitivity and Reproducibility of Fastâ€FLAIR, FSE, and TGSE Sequences for the MRI Assessment of Brain Lesion Load in Multiple Sclerosis: A Preliminary Study. Journal of Neuroimaging, 1997, 7, 98-102.	2.0	20
259	Intra-observer reproducibility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images. Journal of Neurology, 1997, 244, 266-270.	3.6	153
260	A comparison of conventional and fast spin-echo sequences for the measurement of lesion load in multiple sclerosis using a semi-automated contour technique. Neuroradiology, 1997, 39, 161-165.	2.2	25
261	Pattern Visual Evoked Potential Mapping in Alzheimers Disease Correlations with Visuospatial Impairment. Dementia and Geriatric Cognitive Disorders, 1996, 7, 63-68.	1.5	13
262	Brain MRI followâ€up of patients with persistent isolated optic neuritis. European Journal of Neurology, 1996, 3, 36-39.	3.3	2
263	A highâ€resolution threeâ€dimensional T₁â€weighted gradient echo sequence improves the detection of disease activity in multiple sclerosis. Annals of Neurology, 1996, 40, 901-907.	5.3	45
264	Patterns of disease activity in multiple sclerosis patients: A study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups. Journal of Neurology, 1996, 243, 536-542.	3.6	37
265	Semi-automated thresholding technique for measuring lesion volumes in multiple sclerosis: effects of the change of the threshold on the computed lesion loads. Acta Neurologica Scandinavica, 1996, 93, 30-34.	2.1	30
266	Cardiac autonomic function during sleep and wakefulness in multiple sclerosis. Journal of Neurology, 1995, 242, 639-643.	3.6	22
267	Acute myelopathy of unknown aetiology: a clinical, neurophysiological and MRI study of short-and long-term prognostic factors. Journal of Neurology, 1995, 242, 497-503.	3.6	26
268	Nocturnal sleep study in multiple sclerosis: Correlations with clinical and brain magnetic resonance imaging findings. Journal of the Neurological Sciences, 1994, 125, 194-197.	0.6	153
269	Brain magnetic resonance imaging correlates of cognitive impairment in multiple sclerosis. Journal of the Neurological Sciences, 1993, 115, S66-S73.	0.6	95
270	Brain Stem Magnetic Resonance Imaging and Evoked Potential Studies of Symptomatic Multiple Sclerosis Patients. European Neurology, 1993, 33, 232-237.	1.4	27

#	Article	IF	Citations
271	Diffusion and perfusion MRI in inflammation and demyelination. , 0, , 488-500.		0
272	A theory of mind training for people with multiple sclerosis: Development of a scale to assess the treatment acceptability. Current Psychology, 0, , 1.	2.8	1